

This is a repository copy of *RRM adjacent TARDBP mutations disrupt RNA binding and enhance TDP-43 proteinopathy*.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/id/eprint/151546/>

Version: Published Version

Article:

Chen, Han-Jou orcid.org/0000-0001-7875-8661, Topp, Simon D, Hui, Ho Sang et al. (8 more authors) (2019) RRM adjacent TARDBP mutations disrupt RNA binding and enhance TDP-43 proteinopathy. *Brain*. ISSN: 1460-2156

<https://doi.org/10.1093/brain/awz313>

Reuse

This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here:

<https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.

RRM adjacent *TARDBP* mutations disrupt RNA binding and enhance TDP-43 proteinopathy

 Han-Jou Chen,^{1,2} Simon D. Topp,¹ Ho Sang Hui,¹ Elsa Zacco,¹ Malvika Katarya,¹ Conor McLoughlin,¹ Andrew King,³ Bradley N. Smith,¹ Claire Troakes,³ Annalisa Pastore¹ and Christopher E. Shaw^{1,4}

Amyotrophic lateral sclerosis (ALS) presents with focal muscle weakness due to motor neuron degeneration that becomes generalized, leading to death from respiratory failure within 3–5 years from symptom onset. Despite the heterogeneity of aetiology, TDP-43 proteinopathy is a common pathological feature that is observed in >95% of ALS and tau-negative frontotemporal dementia (FTD) cases. TDP-43 is a DNA/RNA-binding protein that in ALS and FTD translocates from being predominantly nuclear to form detergent-resistant, hyperphosphorylated aggregates in the cytoplasm of affected neurons and glia. Mutations in *TARDBP* account for 1–4% of all ALS cases and almost all arise in the low complexity C-terminal domain that does not affect RNA binding and processing. Here we report an ALS/FTD kindred with a novel K181E TDP-43 mutation that is located in close proximity to the RRM1 domain. To offer predictive gene testing to at-risk family members, we undertook a series of functional studies to characterize the properties of the mutation. Spectroscopy studies of the K181E protein revealed no evidence of significant misfolding. Although it is unable to bind to or splice RNA, it forms abundant aggregates in transfected cells. We extended our study to include other ALS-linked mutations adjacent to the RRM domains that also disrupt RNA binding and greatly enhance TDP-43 aggregation, forming detergent-resistant and hyperphosphorylated inclusions. Lastly, we demonstrate that K181E binds to, and sequesters, wild-type TDP-43 within nuclear and cytoplasmic inclusions. Thus, we demonstrate that TDP-43 mutations that disrupt RNA binding greatly enhance aggregation and are likely to be pathogenic as they promote wild-type TDP-43 to mislocalize and aggregate acting in a dominant-negative manner. This study highlights the importance of RNA binding to maintain TDP-43 solubility and the role of TDP-43 aggregation in disease pathogenesis.

- 1 United Kingdom Dementia Research Institute Centre, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, 125 Coldharbour Lane, Camberwell, SE5 9NU, London, UK
- 2 York Biomedical Research Institute, Department of Biology, University of York, Wentworth Way, YO10 5DD, York, UK
- 3 MRC London Neurodegenerative Diseases Brain Bank, De Crespigny Park, SE5 8AF, London, UK
- 4 Centre for Brain Research, University of Auckland, Auckland, New Zealand

Correspondence to: Han-Jou Chen

York Biomedical Research Institute, Department of Biology, University of York, Wentworth Way
YO10 5DD, York, UK

E-mail: han-jou.chen@york.ac.uk

Correspondence may also be addressed to: Christopher E. Shaw

United Kingdom Dementia Research Institute, Maurice Wohl Clinical Neuroscience Institute
Institute of Psychiatry, Psychology and Neuroscience, King's College London, 125 Coldharbour
Lane, Camberwell, SE5 9NU, London, UK
E-mail: chris.shaw@kcl.ac.uk

Keywords: TDP-43; ALS; RNA binding protein; neurodegeneration; protein aggregation

Abbreviations: ALS = amyotrophic lateral sclerosis; FTD = frontotemporal dementia

Received March 29, 2019. Revised July 24, 2019. Accepted August 16, 2019

© The Author(s) (2019). Published by Oxford University Press on behalf of the Guarantors of Brain.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction

Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND), is the most common adult-onset degenerative disease of motor neurons. The disease is characterized by progressive motor neuron loss from the spinal cord, brainstem and motor cortex, which subsequently leads to muscle weakness and eventual respiratory failure. The average age of disease onset is 55 years. Due to its rapid progression, patients typically die within 3 to 5 years of diagnosis. Riluzole remains the only licensed treatment of ALS in the UK, but only marginally extends life expectancy by a few months (Johnston *et al.*, 2006; Wijesekera and Leigh, 2009; Goyal and Mozaffar, 2014). The cause of ALS is not yet completely defined. The majority of ALS patients have no apparent family history of the disease and are categorized as sporadic, whereas ~10% of cases are familial. Regardless of the cause, ~95% of patients share a common molecular pathology featuring the accumulation of ubiquitinated, hyperphosphorylated and detergent resistant TDP-43 protein aggregates in the cytoplasm of affected neuronal tissues (Neumann *et al.*, 2006; Mackenzie *et al.*, 2007; Tan *et al.*, 2007; Geser *et al.*, 2008; Pamphlett *et al.*, 2009; Brettschneider *et al.*, 2013). In 2006, the accumulation of detergent-resistant, hyperphosphorylated TDP-43 was reported in affected neuronal tissues of ALS and frontotemporal dementia (FTD) cases (Neumann *et al.*, 2006). Shortly afterwards, mutations in TDP-43 were found in patients of both familial and sporadic ALS (Sreedharan *et al.*, 2008). To date, there are more than 50 mutations in TDP-43 reported to be associated with ALS or FTD (for a review see Buratti, 2015) that are estimated to account for ~4% of familial ALS and ~1.5% of sporadic ALS (Mackenzie *et al.*, 2010). As TDP-43 cytoplasmic aggregates are observed in ~95% of ALS and tau-negative FTD, the understanding of the mechanisms contributing to the build-up of TDP-43 proteinopathy is critical in unravelling disease development and holds the key to developing effective therapeutic strategies.

TDP-43 is a DNA and RNA binding protein predominantly localizing in the nucleus but also shuttling between the nucleus and cytoplasm. The architecture of TDP-43 comprises an N-terminal domain, two RRM RNA-binding motifs and a C-terminal region often referred to as the 'prion-like' domain, which has low complexity and is enriched for glycine and serine residues. TDP-43 plays a key role in regulating RNA transcription, editing, transport and translation, and is involved in the formation of cellular stress-induced stress granules in the cytoplasm (Belly *et al.*, 2005; Rutherford *et al.*, 2008; Colombrita *et al.*, 2009; Dion *et al.*, 2009; Nonaka *et al.*, 2009). TDP-43 is essential for organism development and survival (Kraemer *et al.*, 2010); however, an excessive amount of the protein causes TDP-43 accumulation, which leads to cytotoxicity and motor deficits (Ash *et al.*, 2010; Barmada *et al.*, 2010; Stallings *et al.*, 2010; Wils *et al.*, 2010). Therefore, it is not

surprising that the cellular levels of TDP-43 are under tight control through a system of autoregulation (Ayala *et al.*, 2011; Polymenidou *et al.*, 2011).

The majority of the TDP-43 disease-causing mutations are in the C-terminal region of the protein. We and others have shown that the C-terminal mutations promote TDP-43 translocation to the cytosol, enhance protein stability and promote the aggregation of the mutant protein which in turn leads to enhanced cytotoxicity *in vitro* and *in vivo* (Johnson *et al.*, 2009; Barmada *et al.*, 2010; Ling *et al.*, 2010; Bilican *et al.*, 2012; Mitchell *et al.*, 2015). As a DNA/RNA-binding protein, TDP-43 plays an important role in RNA regulation and transportation (Colombrita *et al.*, 2009; Lagier-Tourenne *et al.*, 2010). However, the role of RNA binding in the build-up of TDP-43 proteinopathy has never been investigated. In this study, we report a novel FTD/ALS-linked mutation, K181E, which causes catastrophic disruption in TDP-43 protein-RNA binding. Investigating the impact of loss of RNA-binding on TDP-43 proteinopathy further, we demonstrate that mutations that leave TDP-43 incapable of binding RNA promote the accumulation of insoluble aggregates in the nucleus and cytoplasm, suggesting the loss of interaction with RNA can be a factor contributing to the escalation of TDP-43 proteinopathy.

Materials and methods

Patient samples, exome capture and variant analysis

DNA was available for both the index patient and his father. Post-mortem brain and spinal cord tissue was available from the index patient (donated to the London Neurodegenerative Disease Brain bank with informed consent and under the bank's ethical approval: 08/MRE09/38+5). Both patients had a diagnosis of definite ALS based on revised El Escorial criteria (Ludolph *et al.*, 2015), and full consent was given for research purposes. DNA was isolated from whole blood and the exome component captured using Roche NimbleGen SeqCap EZ Exome V3 probes. Sequencing was performed on an Illumina Hi-Seq 2000 and 100-bp paired-end reads assembled to the hg19 human reference genome with NovoCraft Novoalign. Variants were called with samtools mpileup, normalized with bcftools norm and annotated using Annovar and additional custom perl scripts. Variants were quality filtered at DP ≥ 10 , GQ ≥ 50 and MQ ≥ 50 . Variants were excluded if they were present in 1000 Genomes or 670 local control exomes, more than once in UK10K exomes, EVS exomes, or gnomAD genomes, or more than three times in ExAC; frequencies that are comparable to the most common confirmed pathogenic ALS mutations in the ALSoD database. Variants were further excluded if the locus was covered at a depth $\geq 10\times$ by $<10\,000$ ExAC or gnomAD-genome individuals, or if a focused inspection suggested they were false positive variant calls. For this study, gnomAD-exome is not a suitable resource for filtering rare variants as it contains exomes from several thousand patients

with ALS. Assessment of pathogenicity was performed for all non-synonymous variants by 20 different prediction tools available from Annovar. Potential effects on splicing were assessed for variants within 25 bp of a known splice site by ADA, randomForest, Spidex, NetGene2 and GeneSplicer.

Homology modelling of the TDP-43 K181E mutation was performed by Swiss-model, using PDB:4bs2 as a template, and all images were rendered in PyMOL.

Immunohistochemistry

Sections of 7- μ m thickness of human spinal cord tissue samples in 10% formalin-fixed, paraffin-embedded tissue blocks were obtained from the London Neurodegenerative Diseases Brain Bank. The paraffin-embedded tissue blocks were deparaffinized in two changes of xylene and sequential percentage of ethanol solutions for 3 min each (100%, 100%, 95%, 95%, 70%). Antigen retrieval was performed by soaking the slides in 10 mM citrate buffer pH 6.0 and microwaved for 15 min. For diagnosis, paraffin sections were stained for haematoxylin and eosin and sections were immunohistochemically stained with the rabbit polyclonal antibody to phosphorylated TDP-43 (pS409/410-2; 1:1500 Cosmo Bio); mouse monoclonal antibody to phosphorylated tau [clone (AT-8); 1:500; Autogen Bioclear], α -synuclein [clone (42/ α -synuclein); 1:500; Novocastra Laboratories Ltd.], and amyloid- β (1:12 000; Chemicon), using the Leica BONDMAX™ (Leica Biosystems). Heat induced epitope retrieval was used for all antibodies except for α -synuclein and amyloid- β . For α -synuclein, and amyloid- β , 80% formic acid pretreatment was used. Nuclei were counterstained with Harris' alum haematoxylin. For immunofluorescence staining, autofluorescence was blocked by the treatment of Sudan black (0.06 g in 20 ml of 70% ethanol) for 10 min. After blocking in normal serum, the sections were stained and imaged as described in the 'Immunofluorescence' section.

Plasmids and antibodies

The GFP-TDP-43 in pEGFP-C1 and HA-TDP-43 in pDEST30 plasmids were generated and used as in previous studies (Nishimura *et al.*, 2010; Scotter *et al.*, 2015; Chen *et al.*, 2016). TDP-43 mutations were introduced using the Q5 Site-Directed Mutagenesis Kit (NEB) with the following mutagenesis primers: K181E forward 5'-CTTCCTAATTCTGAGC AAAGCCAAG-3' and reverse 5'-GAACCGAAACGAGTCT TAATCCTTC-3'; K181A forward 5'-CTTCCTAATTCT GCGCAAAGCCAAG-3' and reverse 5'-TTTGCAGTCACAC CATCG-3'; D169G forward 5'-CATATGATAGGTGGAC GATGG-3' and reverse 5'-TCGCTGTGACATTACTTTC-3'; K263E forward 5'-CCGAACCTGAGCACAATAGC-3' and reverse 5'-CATTGGATATATGAACGCTGATTCC-3'. All plasmid sequences were verified by Sanger DNA sequencing.

Primary antibodies used for immunoblotting and immunohistochemistry in this study included: mouse anti-phospho TDP-43 (1:3000, Cosmo Bio), rabbit anti-mouse TDP-43 (0.1 μ g/ml, a gift from Prof. Virginia Lee) (Igaz *et al.*, 2011), mouse anti-Actin (1:4000, Sigma), mouse anti-GFP (1:1000, Santa Cruz), rabbit anti-TDP-43 (1:2000, Proteintech), mouse anti-GFAP (1:1000, Abcam) and mouse anti-HA (1:1000, Cell Signaling). Primary antibodies used for immunopurification included rabbit anti-GFP (1:2000, Abcam) and

rabbit anti-HA (C29F4) (1:500, Cell Signaling). Primary antibodies used for immunofluorescence included rabbit anti-ubiquitin, K48-specific (1:2000, Millipore), rabbit anti-p62 (1:10 000, Abcam), mouse anti-phospho TDP-43 (1:3000, Cosmo Bio) and rabbit anti-TDP-43 (1:2000, Proteintech).

Secondary antibodies used included DyLight™ 680 goat anti-rabbit IgG (1:10 000, Thermo Scientific), DyLight™ 800 goat anti-mouse IgG (1:10 000, Thermo Scientific), and DyLight™ 488/550/650 anti-rabbit or mouse IgG (1:500, Thermo Scientific).

Protein construct production and purification for *in vitro* study

The wild-type tandem RRM domains of TDP-43 (RRM1-2, K102-Q269) and the corresponding K181E mutant variant were encoded in a pET-Sumo expression vector containing the kanamycin antibiotic resistance gene. The plasmids were expressed in a Rosetta2(DE3) *Escherichia coli* cell strain as proteins fused with a SUMO solubilization tag carrying a 6 \times His tag. Cells were grown in Luria-Bertani (LB) medium containing 50 μ g/ml kanamycin at 37°C until an optical density of \sim 0.7 at 600 nm was reached. Protein expression was induced at 18°C by addition of 0.5 mM IPTG. Cells were collected after overnight growth and resuspended in lysis buffer (10 mM potassium phosphate buffer pH 7.2, 150 mM KCl, 5 mM imidazole, 5% v/v glycerol, 1 mg/ml lysozyme, cOmplete™ EDTA-free Protease Inhibitor tablet by Roche, 1 μ g/ml DNase I and 1 μ g/ml RNaseA). Cells were lysed by probe sonication and the soluble proteins recovered by centrifugation at 70 000 rcf for 45 min at 4°C. Protein purification included a first nickel affinity chromatography step followed by overnight dialysis in the presence of the Tobacco Etch Virus (TEV) protease at a 1:20 protein:TEV molar ratio to remove the 6 \times His-SUMO tag. A second nickel-affinity chromatography followed and the flow-through was loaded onto a HiTrap® Heparin column to remove nucleic acids. The protein constructs were finally submitted to size-exclusion chromatography with a HiLoad® 16/60 Superdex 75 prep grade in phosphate buffer pH 7.2. Protein purity was checked by SDS-PAGE.

Spectroscopic measurements

Circular dichroism (CD) spectra were recorded on a JASCO-1100 spectropolarimeter with a constant N₂ flush at 4.0 l/min. CD datasets were an average of 15 scans. Far-UV spectrum was recorded at 25°C in phosphate buffer, pH 7.2. Spectra were corrected for buffer signal and expressed as mean residue molar ellipticity θ (deg \times cm²/dmol).

Uniformly and selectively ¹⁵N-labelled versions of wild-type RRM1-2 and the K181E mutant were produced by standard methods (Marley *et al.*, 2001). 2D nuclear magnetic resonance (NMR) ¹⁵N-HSQC (heteronuclear single quantum coherence) spectra were recorded at 700 MHz frequency at 25°C on Varian spectrometers.

Aggregation kinetics assay

Protein aggregation was monitored by following the increment in emission fluorescence of the aggregate-specific dye

Proteostat® on a FLUOstar Omega plate reader. Proteins were diluted in phosphate buffer pH 7.2 to a concentration of 10 µM, with and without equal amount of the AUG-RNA (5'-GUGUGAAUGAAU-3'). The plate was sealed with an optic seal and the assay plates were incubated at 37°C under, shaking for 2 s (≈200 rpm) before each read (every 15 min). The experiments were performed at least in triplicate and the results referred to the blank, normalized and reported as percentage average.

Cell culture and DNA transfection

HEK293T and SH-SY5Y cells were cultured using Dulbecco's modified Eagle medium (DMEM) and DMEM/F12 (Invitrogen) supplemented with 10% foetal bovine serum (Invitrogen), and maintained at 37°C, 5% CO₂. Cells were plated a day before transfection and media was refreshed before plasmid DNA transfection using Lipofectamine™ 2000 (Invitrogen). Cells were left for 48 h after transfection to be harvested for analysis unless otherwise stated.

RNA extraction and RT-PCR

RNA was extracted using RNeasy® Mini Kit (Qiagen). cDNA was generated using 1 µg of RNA, oligo d(T) primer and SuperScript™ III First-Strand Synthesis Kit (Invitrogen). Fifty nanograms of cDNA was used for RT-PCR with forward primers labelled with IRDye 700 at the 5' end. Primers used in this study included: *POLDIP3* forward 5'-TGCTCTGAAG CTCACCAAAA-3' and reverse 5'-GGAACGGAAGCTATAC CATCAT-3' (Tollervy *et al.*, 2011); *EGFP* forward 5'-CTG AAGTTCATCTGCACCAC-3' and reverse 5'-GGTCTTGTAG TTGCCGTCG-3'; *GAPDH* forward 5'-CCTGACCTGCCGTC TAGAAA-3' and reverse 5'-ATCCTGGTGCTCAGTGTAGC C-3'. RT-PCR products were analysed by 2% agarose gel. Images were taken by the Odyssey or GelDoc imaging system and quantified by ImageJ (<http://imagej.nih.gov/ij/>).

Solubility fractionation

The fractionation for protein solubility was performed using a protocol described by Winton *et al.* (2008) with some minor modifications (Chen *et al.*, 2016). Cells were harvested in RIPA buffer (150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris pH 8.0 and protease and phosphatase inhibitors), sonicated and centrifuged at 12 000g for 20 min at 4°C. After centrifugation, the supernatant was collected as the RIPA solubility fraction. The pellet, after being washed once with RIPA buffer, was then suspended in 20% of the original lysis volume with urea buffer (7 M Urea, 2 M thiourea, 4% CHAPS and 30 mM Tris pH 8.5) and collected as the insoluble, detergent-resistant fraction.

Immunopurification

Cells were harvested in IP buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1% Triton™ X-100 with protease and phosphatase inhibitor). After a short centrifuge (14 000 rpm for 30 s at 4°C), the supernatant was collected and pre-cleaned with Dynabead® protein G (Invitrogen) 2 h at 4°C. The pre-cleaned lysate was then incubated with immunopurification antibody and fresh Dynabead® protein G (Invitrogen) overnight at 4°C.

The Dynabead® protein G-antibody-protein complex was purified using magnetic separation and washed with IP buffer before elution in loading buffer.

Western blotting and densitometry analysis

Protein quantification and western blotting were performed as described before (Nishimura *et al.*, 2010; Chen *et al.*, 2016). Five micrograms of cell lysate from the RIPA fraction and the equivalent liquid volume from the urea fraction were loaded. Western blot quantification were performed used the image analysis software, ImageJ (<http://imagej.nih.gov/ij/>). Integrated band intensities were normalized to that of loading control or the RIPA fraction.

Immunofluorescence

Cells for immunofluorescent analyses were fixed in 4% paraformaldehyde (VWR) for 20 min and washed with phosphate-buffered saline (PBS) three times for 5 min. Cells were permeabilized by incubation in PBS containing 0.5% Triton™ X-100 (Sigma) for 15 min at room temperature, followed by blocking in PBS containing 1% donkey serum for 1 h at room temperature. Cells were incubated with primary antibody diluted in blocking solution overnight at 4°C. After washing in PBS, cells were subsequently incubated with fluorescent secondary antibodies diluted in blocking solution for 1 h at room temperature. DAPI (Sigma) was then used to stain for nuclei before being mounted on coverslips using FluroSave (Calbiochem).

RNA electrophoretic mobility-shift assay

Using the LightShift Chemiluminescent RNA EMSA Kit (electrophoretic mobility-shift assay, EMSA) (Thermo Fisher), 5 µg of total cell lysate in RIPA containing RNase inhibitor (NEB) was mixed with 2 µg of tRNA, 1 µM of unlabelled (GU)×6 RNA and 2.5 nM of biotin-labelled (GU)×6 RNA (CGUGUGUGUGUGUGGU) (Bhardwaj *et al.*, 2013) and was incubated for 30 min at room temperature. The binding reactions were run on a 6% non-denaturing polyacrylamide gel, followed by semi-dry transfer (3 mA/cm², 30 min) to Hybond-N+ nylon membrane (GE Healthcare) and UV cross linking (120 mJ/cm²). Biotin-labelled RNA was detected by chemiluminescence with stabilized streptavidin-horseradish peroxidase conjugate provided by the RNA EMSA kit.

Fluorescence recovery after photobleaching

HEK293T cells (10⁶) per well were plated on the 15µ-Slide 8 well chamber slide (Ibidi) the day before transfection. Cells were transfected with GFP-TDP-43 for 48 h and Hoechst staining (1 mg/ml, Thermo Fisher) was applied 20 min before imaging.

Fluorescence recovery after photobleaching (FRAP) was performed using a Nikon A1R laser scanning confocal

microscope fitted with an environmental chamber maintained at 37°C. Confocal images of 512 × 512 pixels were acquired using a ×60 oil immersion objective. Five frames were acquired before bleaching (10% laser power, 4 frames/s of 10 loops) a 3 × 3 μm² region of interest. Fluorescence recovery was followed for 1 min after bleaching. Data analysis was performed using Nikon Elements software as per manufacturer's instruction. The EGFP fluorescence intensity at each time point was measured for the bleached region of interest as well as for an unbleached reference region of interest of the same size to correct for acquisition bleaching. FRAP recovery for the bleached region of interest was calculated by first subtracting the reference at each time point and then normalized to the pre-bleached fluorescence intensity.

Data availability

The data supporting the findings of this study are available from the corresponding author on request.

Results

Identification of novel RRM-adjacent TARDBP mutation in a familial ALS/FTD kindred

A 38-year-old male patient presented with predominantly lower motor neuron signs that progressed over 48 months to a flaccid tetraparesis, but he was still able to speak and had normal cognitive function. His father developed lower motor neuron signs in his upper limbs at the age of 76 and 6 months later developed major personality and behavioural changes consistent with a clinical diagnosis of FTD that eventually led to profound cognitive deficits. Brain MRI was consistent with a diagnosis of FTD. The index patient survived 80 months from symptom onset and his father survived 36 months (Fig. 1A). The brain and spinal cord tissues from the index patient were available for further neuropathological examination.

The formalin fixed left half of the brain weighed 782 g. There was some slight cerebral swelling noted but no cerebral atrophy. No other macroscopical abnormality was seen in the brain. The spinal cord did show some evidence of thinning of anterior nerve roots. Histologically the spinal cord showed loss of anterior horn neurons and some surviving neurons contained Bunina bodies [Fig. 1B(i)]. Immunohistochemistry revealed phosphorylated (p)TDP-43-positive skein-like inclusions in the neurons [Fig. 1B(ii)], and numerous pTDP-43-positive cytoplasmic inclusions in glial cells [Fig. 1B(iii)]. There was loss of myelin in the lateral and anterior corticospinal tracts of the cord, indicating upper motor neuron loss. Indeed within the motor cortex there was loss of Betz cells, and many surviving Betz cells contained pTDP-43-

positive neuronal [Fig. 1B(iv)] cytoplasmic inclusions. There were pTDP-43-positive neuronal [Fig. 1B(v)] and glial cytoplasmic inclusions in the XIIth nerve nucleus of the medulla, and also the midbrain, basal ganglia and amygdala but not the hippocampus or neocortex. The glial cells containing cytoplasmic TDP-43 inclusions were GFAP-positive (Fig. 1C) but MBP- or CD68-negative (data not shown), showing that cytoplasmic TDP-43 accumulation was present in astrocytes but not seen in oligodendrocytes or microglia. There was no tau, amyloid-β or α-synuclein pathology present.

NimbleGen exome capture and Illumina sequencing were carried out on whole blood DNA for both the father and son, resulting in 134 million and 160 million 100-nucleotide paired-end reads, respectively, which when assembled to the human reference genome, covered 91.76% of the coding bases in Refseq to a depth ≥10× in both samples. A relaxed filtering strategy identified 29 candidate variants present in both affected family members (Supplementary Table 1), 11 of which were not present in the 1000 Gnomes, UK10K, EVS/ESP, ExAC, or gnomAD variant databases, nor in 670 local controls. One of these variants was of paramount interest as it represented a novel missense change in the RNA-binding domain of TDP-43 (TARDBP: NM_007375:c.541 A>G:p.Lys181Glu) (K181E), predicted to be damaging by 15 of 20 prediction tools used to assess pathogenicity. The heterozygous mutation of TDP-43 K181E was validated with Sanger DNA sequencing (Fig. 1D) and is predicted to substitute a positively-charged lysine (K) residue adjacent to the first RNA-binding domain with a negatively-charged glutamic acid (E). The K181E mutation lies adjacent to the RRM1 whereas most ALS-associated mutations cluster at the 'prion-like' domain (Fig. 1E).

The structure of the tandem RRM domains is not altered by the K181E mutation

We speculated on a possible destabilizing effect of the K181E mutation on the structure of TDP-43. Because of the known difficulties in working with full-length TDP-43 *in vitro* (Johnson *et al.*, 2009), we produced a construct containing the two tandem RRM domains of TDP-43, here called RRM1-2, as heterologous protein expressed in *E. coli*, both as wild-type and as a K181E mutant to investigate the mutation effect.

CD spectroscopy was used to compare the overall secondary structure of the two variants (Fig. 2A). Both spectra displayed the signature typical of folded α-β proteins and overlapped both in shape and signal intensity, indicating that the secondary structure is not altered by the K181E mutation. We also investigated the potential local effect of the mutation by NMR HSQC spectroscopy (Fig. 2B). The




Figure 1 Identification of the K181E mutation in a family of ALS/FTD. (A) The pedigree of the ALS/FTD kindred carrying the K181E mutation is shown. Affected individuals are indicated by shaded symbols, deceased individuals with a slash, and numbers indicate current age or age at death. (B) Brain and spinal cord pathology of index patient. [B(i)] Bunina bodies (arrow) observed in a slightly atrophic anterior horn neuron from the spinal cord. [B(ii)] Granular/skein-like pTDP-43-positive cytoplasmic inclusion in an atrophic anterior horn neuron from the spinal cord. [B(iii)] A pTDP-43-positive glial cytoplasmic inclusion within the spinal cord. [B(iv)] A motor neuron from the motor cortex containing granular cytoplasmic pTDP-43-positive inclusions. [B(v)] The XIIth nerve nucleus of the medulla showing skein-like (arrowhead) and granular (black arrow) cytoplasmic pTDP-43-positive neuronal inclusions. Scale bar = 50 μ m in i, ii, iv, v; 20 μ m in iii. (C) Cytoplasmic TDP-43 [C(i), arrow] and p-TDP-43-positive inclusions [C(ii), arrows] observed in GFAP-positive cells. Images were taken in the area of anterior horn from the spinal cord. Scale bar = 5 μ m. (D) Sanger sequencing chromatogram demonstrating a wild-type control and a heterozygous single base substitution (c.541A>G) predicted to substitute lysine for glutamic acid (p.Lys181Glu, K181E) in the index patient and his father. (E) Schematic overview of TDP-43 protein domain structure and disease-associated mutations.

2D spectra resulted highly similar, both in terms of chemical shifts and relative resonance intensities, indicating that mutation of K181 to E does not affect the chemical environment of the protein.

These results clearly exclude that the K181E mutation could alter the structure of the tandem RRM motifs and led us to believe that the effect on the native conformation of full-length TDP-43 is not structural.




Figure 2 Structural comparison of the wild-type and K181E tandem RRM domains. (A) CD spectra acquired at room temperature, indicating almost complete overlap in their secondary structure. (B) Superposition of heteronuclear single quantum coherence (HSQC) experiments showing that the two variants have nearly identical NMR spectra. Black = wild-type RRM1-2; red = K181E RRM1-2.

K181E decreases TDP-43 protein solubility and enhances hyperphosphorylation

In ALS and FTD, pathological TDP-43 protein accumulates in affected neurons, forming hyperphosphorylated and detergent-resistant aggregates. In an earlier study, we observed elevated levels of insoluble and hyperphosphorylated TDP-43 following the overexpression of both wild-type and ALS-associated C-terminal TDP-43 mutants (Chen *et al.*, 2016). To investigate whether the novel RRM-domain K181E mutation is pathological and causes TDP-43 aggregation, we used the same cellular model transiently overexpressing EGFP-tagged full length TDP-43 in HEK293T cells. Levels of C-terminal mutant M337V and Q331K protein in the urea-soluble fraction was similar to wild-type protein but levels of insolubility and phosphorylation of the K181E mutant protein were increased 2- to 4-fold, respectively (Fig. 3). Similar results were also found when the same EGFP-TDP-43 constructs were expressed in the neuroblastoma cell line, SH-SY5Y (Supplementary Fig. 1), validating the profound effect of the K181E mutation in enhancing features of TDP-43 proteinopathy. Although the K181E mutation lies well outside the C-terminal domain and does not have a significant impact on the structure of the RRM1-2 area (Fig. 2), the increased levels of hyperphosphorylated and insoluble TDP-43 protein are consistent with it being pathological.

K181E disrupts TDP-43 binding to target RNA and promotes nuclear aggregation

The majority of ALS-associated TDP-43 mutations have so far been found to occur within the low complexity ‘prion-

like’ C-terminal domain (amino acids 274 to 414, Fig. 1E), which is involved in interactions with other proteins (Buratti *et al.*, 2005; D’Ambrogio *et al.*, 2009; March *et al.*, 2016). Although the mechanism(s) of C-terminal mutant protein toxicity are not clear, they have a longer half-life than wild-type TDP-43 and are more prone to form cytoplasmic aggregates (Barmada *et al.*, 2010; Ling *et al.*, 2010). The K181E mutation, however, is adjacent to the RRM1 domain, which plays a dominant role in DNA and RNA binding (Buratti and Baralle, 2001; Kuo *et al.*, 2009; Che *et al.*, 2015). The crystal structure of a peptide containing both TDP-43 RRM domains bound to a GU-rich-RNA strand has been resolved (PDB:4bs2) and shows that the lysine residue at 181 lies within one wall of a pocket-like cavity into which a guanine nucleotide is bound (Fig. 4A, B and Supplementary Video 1; Lukavsky *et al.*, 2013). As the lysine residue is positively charged, it will have a greater affinity for negatively-charged DNA or RNA nucleotides than the negatively-charged mutant glutamic acid (E), which is predicted to create an electrostatic repulsion between the protein and the nucleotide (Fig. 4B) that could reduce the RNA-binding capacity of TDP-43. We therefore investigated the interaction between the TDP-43 protein and a known RNA target, (GU) \times 6 (Bhardwaj *et al.*, 2013) using an electromobility shift assay (EMSA). Wild-type GFP-TDP-43 showed highly efficient binding to (GU) \times 6 RNA, as did Q331K and M337V TDP-43 (Fig. 4C); however, this interaction was completely abolished by the K181E mutation (Fig. 4C). This loss of RNA-binding of K181E TDP-43 was also shown by its inability to regulate the splicing of its target RNAs, such as *POLDIP3* (Fig. 4D and E). Wild-type, Q331K and M337V all enhanced the exclusion of *POLDIP3* exon 3 but K181E failed to splice out this exon (Fig. 4D and E). Interestingly, in addition to the occasional cytosolic hyperphosphorylated aggregates seen in wild-type TDP-43




Figure 3 The K181E mutation increases TDP-43 detergent-resistance and phosphorylation. (A) HEK293T cells expressing GFP-TDP-43 constructs for 48 h, followed by fractionation. Phospho-TDP-43 specific antibody is used to visualize phospho-TDP-43 and TDP-43 antibody for total overexpressed GFP-TDP-43. Levels of GFP-TDP-43 (B and C) and phospho-TDP-43 (D) from three independent transfections were quantified, normalized to actin and shown in relation to GFP-WT TDP-43. Mean and standard error of the mean (SEM) are shown for the soluble (B), and insoluble (C and D) fractions. The data were analysed by one-way ANOVA followed by Bonferroni post-test. Significant increases in detergent-resistance and protein phosphorylation is found with K181E-TDP-43 ($P < 0.01$ for both). WT = wild-type.

overexpression, K181E TDP-43 frequently formed nuclear aggregates that were also hyperphosphorylated (Fig. 4F), which implies that RNA binding in the nucleus may prevent aberrant TDP-43 aggregation.

The impact of K181E mutation on RNA interaction observed in RNA-EMSA was validated in an *in vitro* study where we used the RRM1-2 wild-type and K181E mutant constructs and determined the dissociation constant (K_d) of the interaction with AUG RNA by means of bio-layer interferometry. We found that wild-type RRM1-2 binds the UG-rich AUG RNA with a K_d of 3.2 ± 0.9 nM, while the K181E mutant displayed a K_d of 2.5 ± 0.4 μ M (Supplementary Fig. 2).

We can thus conclude that, while not having any structural relevance, the mutation leads to severe impairment of function and prevents the interaction between TDP-43 protein and its target RNA, which is crucial for effective splicing and trafficking. Our data have also shown that the

K181E-TDP-43 is unable to bind and process RNA and is highly prone to aggregation.

Disruption of RNA binding enhances TDP-43 phosphorylation and aggregation

To dissect the relationship between RNA binding and TDP-43 proteinopathy further, we extended our study to other missense variants that occur in or around the RRM domains, including K181A, D169G and K263E. The K181A variant is an artificial construct generated to test the affinity of RNA for the RRM1 of TDP-43, which was shown to be unaffected (Fig. 5A; Lukavsky *et al.*, 2013). The D169G mutation was identified in one sporadic ALS case (Kabashi *et al.*, 2008) and shown not to have any impact on RNA binding in *in vitro* studies despite its location at




Figure 4 The K181E mutation disrupts the interaction between TDP-43 protein and RNA interaction, which prevents splicing of target RNA and increases TDP-43 aggregating. (A) Crystal structure of TDP-43 N-terminal fragment (pdb:4bs2) containing two RRM domains (red helices, yellow beta sheets) interacting with a GU-rich RNA strand (blue/orange spheres), showing TDP-43 lysine 181 (purple spheres) to be in close contact with a guanine nucleotide. (B) Close-up of the guanine-binding pocket formed by D105, F149, K181, R197 and S254 (i) is not altered structurally altered by the E181 mutation (ii); however, the positively-charged cavity (iii) gains a strongly negative electrostatic charge in the presence of the ALS-linked mutation (iv). (C) RNA-EMSA using total cell lysate from 48 h GFP-TDP-43 transfected HEK293T cells and biotin-labelled (GU) × 6 RNA. Western blots (WB) of GFP-TDP-43 actin are used to demonstrate uniform expression of GFP-TDP-43 and protein loading; $n = 3$. (D) Endogenous *POLDIP3* mRNA splicing assay using RNA extracted from 48 h GFP-TDP-43 transfected HEK293T cells. RT-PCR for *POLDIP3*, *EGFP* and *GAPDH* was carried out to show the TDP-43-mediated mRNA splicing activity, transfection efficiency and loading. (E) The levels of *POLDIP3* long and short transcripts from three independent studies were quantified. Means and SEMs are shown. The data were analysed by one-way ANOVA followed by Bonferroni post-test. Wild-type, Q331K- and M337V-TDP-43 significantly alter the splicing profile of *POLDIP3* ($P < 0.05$) whereas K181E-TDP-43 does not have any significant impact, compared to untransfected or GFP-only control. (F) Phospho-TDP-43 staining (red) in HEK293T cells transfected for 48 h with GFP wild-type or K181E-TDP-43. Scale bar = 10 μ m.




Figure 5 Disruption of RNA binding enhances TDP-43 protein aggregation and phosphorylation. (A) RNA EMSA using total cell lysate from 48 h GFP-TDP-43 transfected HEK293T cells and biotin-labelled (GU) \times 6 RNA. Western blots of GFP-TDP-43 and actin demonstrate the equal expression of GFP-TDP-43 constructs and protein loading. (B and C) HEK293T cells express GFP-TDP-43 constructs for 48 h followed by fractionation. GFP or phospho-TDP-43-specific antibody was used to visualize total GFP-TDP-43 (B) or phospho-TDP-43 (C). (D and E) Phospho-TDP-43 staining (red) in HEK293T cells transfected for 48 h with GFP-TDP-43. Scale bar = 10 μ m. Cell counting was carried out manually under fluorescence microscope. At least 200 GFP-positive cells were counted for each condition, per transfection, using an unbiased protocol as described previously (Lee et al., 2013). One-way ANOVA and Bonferroni post-test shows that there are significantly more nuclear TDP-43-containing cells in both K181E- and K263E-TDP-43-expressing conditions ($P < 0.0001$). (F and G) FRAP was carried out after 48 h of GFP-TDP-43 transfection in HEK293T cells. A $3 \times 3 \mu\text{m}^2$ area (indicated with white box) was bleached with fluorescence and recovery recorded for 1 min after bleaching. Hoechst 33342 staining (blue) was used to visualize the nucleus. Scale bar = 10 μ m. Five cells were bleached and recorded for each condition, per transfection. Means and SEMs of three transfections are plotted in G. (H and I) Fluorescence-associate aggregation kinetics in the absence and presence of RNA. The percentage of aggregation reduction of the wild-type-RRM1-2 (H) or K181E-RRM1-2 (I) protein constructs due to the presence of RNA is indicated by an arrow at a 1:1 protein:RNA molar ratio. All experiments were repeated at least three times.

the RRM1 domain (Fig. 5A; Austin *et al.*, 2014; Kuo *et al.*, 2014), nor functional disruption to full length TDP-43 (McDonald *et al.*, 2011; Vanden Broeck *et al.*, 2015). We were able to confirm that neither K181A nor D169G variants disrupt RNA binding (Fig. 5A). Alanine has a neutral charge and is therefore less likely to repel nucleotides at position 181, while the substitution of aspartic acid (D) to glycine (G) at position 169 is distant from the RNA-binding interface and unlikely to cause direct steric or electrostatic disruption (Supplementary Fig. 3). K263E was identified in one patient diagnosed with sporadic FTD (Kovacs *et al.*, 2009) and in cellular studies this mutation was shown to increase TDP-43 stability and enhance its ubiquitination (Austin *et al.*, 2014; Hans *et al.*, 2014). Here we show that, like K181E, the K263E mutation also disrupts the capacity of TDP-43 to bind RNA (Fig. 5A). Interestingly, K263 in the RRM2 domain shares structural and functional homology with the K181 residue in the RRM1 domain, in that it contributes to forming a positively-charged groove into which a guanine nucleotide is shown to fit. The negatively-charged glutamic acid (E) residue in this position in the RRM2 domain is also predicted to repel negatively-charged nucleotides and inhibit RNA binding.

The K181E and K263E mutants also had much higher levels of phosphorylation and reduced solubility compared to wild-type- and the D169G-TDP-43 mutation on western blots (Fig. 5B and C) and were more likely to form phosphorylated intra-nuclear aggregates (30% of transfected cells, Fig. 5D and E) compared to wild-type-, D169G- and K181A-TDP-43, which have a diffuse distribution in the nucleus (Fig. 5D and E). Although K181A did not disrupt RNA binding in our *in vitro* assay (Fig. 5A), it did show a modest increase in detergent-resistant phosphorylated intra-nuclear aggregates (Fig. 5C and D). FRAP analysis of the nuclear TDP-43 aggregates demonstrated that they were highly immobile compared to diffuse nuclear wild-type, D169G or M337V TDP-43, or the nuclear localization signal (NLS) deleted cytoplasmic (dNLS) TDP-43 (Fig. 5F, G and Supplementary Videos 2 and 3).

Recently, we showed that UG-rich RNA can significantly reduce the aggregation of TDP-43 RNA-recognition regions (Zacco *et al.*, 2019). We used the aggregation detection fluorophore ProteoStat, which allows us to monitor aggregate formation as a function of time. We normalized the data as referred to the value reached at end of the assay (3 days). In the absence of UG-rich RNA, wild-type RRM1-2 exhibited time-dependent self-assembly (Fig. 5H). When RNA was added in a 1:1 ratio, the percentage of aggregates recorded for the wild-type after 3 days was only 34% the value detected in the absence of RNA, indicating a RNA-dependent aggregation inhibition of RRM1-2 aggregation of 66% (Fig. 5H). When the same level of RNA was added to the K181E mutant aggregate formation was reduced only by 5% (Fig. 5I), suggesting that the weak interaction with this RNA translate into a weak inhibitory effect on the aggregation behaviour.

The amino acids surrounding K181 are the most conserved region in TDP-43, in particular the 109 amino acids from the C-terminal half of RRM1 (Phe152) to the end of RRM2 (Ala260), which are completely devoid of any nonsense or missense variants in the ExAC database (Supplementary Fig. 4). This high level of conservation indicates that this region plays a crucial role in TDP-43 functionality and that there has been a strong selection pressure against changes to the RRM domains. Specific mutations such as K181E and K263E in this highly conserved region disrupt RNA binding and promote the accumulation of detergent resistant, hyperphosphorylated, immobile nuclear TDP-43 aggregates conferring likely pathogenicity. It is also interesting to note that the capacity to interact with RNA may play an important role in maintaining TDP-43 solubility and functionality.

K181E-TDP-43 interacts and recruits wild-type endogenous TDP-43 protein to nuclear aggregates

TDP-43 is an aggregation-prone protein that forms oligomers under physiological conditions and detergent-resistant aggregates in disease and overexpression cellular and transgenic models (Neumann *et al.*, 2006; Mitchell *et al.*, 2015; Chen *et al.*, 2016; Afroz *et al.*, 2017). To investigate the interaction between mutant and wild-type proteins, we co-expressed wild-type and K181E HA- and GFP-tagged constructs (Fig. 6A). Overexpression of haemagglutinin (HA)- and GFP-tagged wild-type-TDP-43 generated occasional hyperphosphorylated TDP-43 cytoplasmic aggregates that consisted of both HA- and GFP-wild-type TDP-43 proteins. Co-aggregation was far more abundant in wild-type- and K181E-TDP-43 co-expressing cells predominantly within the nucleus (Fig. 6A and B). The interaction between wild-type- and mutant-TDP-43 proteins was confirmed as co-immunoprecipitation of HA-tagged wild-type and mutant TDP-43 consistently pulled down the GFP-tagged wild-type TDP-43 protein, which was most abundant with HA-K181E and K263E bait (Fig. 6C). Thus aggregation of mutant or wild-type protein in the cytoplasm or nucleus is able to recruit endogenous wild-type protein (Fig. 6D) and could thereby interfere with RNA processing.

In summary, we have shown that although K181E and K263E ALS and FTD-associated mutants of TDP-43 do not directly bind RNA, they are able to disrupt RNA processing by sequestering endogenous wild-type TDP-43 protein within hyperphosphorylated aggregates, which could have significant functional consequences.

Disruption of cytoplasmic TDP-43 RNA binding aggravates TDP-43 proteinopathy

TDP-43 is predominantly a nuclear protein; however, it is known to shuttle between the nucleus and cytoplasm,




Figure 6 K181E mutant TDP-43 binds to wild-type-TDP-43 and sequesters it in phosphorylated intranuclear and cytoplasmic inclusions. (A and B) HEK293T cells co-expressing GFP WT- or K181E-TDP-43 and HA WT-TDP-43 for 48 h were fixed and stained with HA (red) and phospho-TDP-43 (magenta). Cytoplasmic hyperphosphorylated TDP-43 aggregates (arrowhead) were seen in both conditions; nuclear hyperphosphorylated aggregates containing both wild-type (WT) and K181E-TDP are indicated by arrows. (C) Co-immunoprecipitation of GFP-WT or mutant TDP-43 and HA wild-type-TDP-43. HA WT-TDP-43 was pulled down by the HA antibody and GFP-TDP-43 detected with the TDP-43 antibody. (D) Interaction between GFP-K181E TDP-43 and endogenous wild-type TDP-43 in the mouse neuronal cell line, N2a. After 48 h transfection with GFP-TDP-43, cells were fixed and stained by phospho-TDP-43-specific antibody (red) and the mouse TDP-43-specific antibody (magenta). Scale bar = 10 μ m. All experiments were repeated at least three times.

playing a crucial role in regulating RNA transport, metabolism and local cytoplasmic translation (Liu-Yesucevitz *et al.*, 2011; Fallini *et al.*, 2012; Yasuda and Mili, 2016). To investigate the influence of RNA binding on the behaviour of cytoplasmic TDP-43, we introduced the K181E mutation into a TDP-43 construct lacking the nuclear localizing signal (GFP-dNLS TDP-43), which is preferentially retained in the cytoplasm. Interestingly, the K181E mutation substantially increased levels of hyperphosphorylated TDP-43 detergent resistant aggregates (Fig. 7A–C and Supplementary Fig. 5A), which were localized to the cytoplasm in both HEK293T and SH-SY5Y cells (Fig. 7B, C and Supplementary Fig. 5B). Protein aggregates associated with neurodegenerative disorders are often decorated with proteins that facilitate protein degradation such as ubiquitin and p62 (Arai *et al.*, 2003; Neumann *et al.*, 2006). Although nuclear and cytoplasmic aggregates of wild-type and mutant TDP-43 were labelled with ubiquitin, p62 stains more intensively with cytoplasmic aggregates and weaker with nuclear aggregates associated with the K181E mutation (Fig. 7D and E).

The formation of hyperphosphorylated TDP-43 cytoplasmic and, less commonly, nuclear aggregates, are a hallmark feature of ALS and FTD, but the factors that contribute to their development are not fully understood. We have confirmed that some disease-associated mutations adjacent to RRM1 and RRM2 disrupt RNA binding and form nuclear and cytoplasmic aggregates. This may impair RNA processing through the sequestration of wild-type protein, acting in a dominant-negative fashion. Furthermore, the binding to its target RNA plays an important role in maintaining the solubility of TDP-43 protein. Disruption of RNA binding promotes TDP-43 to aggregate in the cytoplasm as well as in the nucleus.

Discussion

Mutations in *TARDBP* linked to ALS and FTD and are associated with phosphorylated cytoplasmic TDP-43 aggregates in degenerating neurons (Sreedharan *et al.*, 2008; Kovacs *et al.*, 2009; Synofzik *et al.*, 2014). Using exome sequencing, we detected a novel K181E *TARDBP* mutation in a father and son with classical ALS/FTD and ALS, respectively, and we excluded mutations in all other known ALS and FTD genes. More than 90% of all TDP-43 mutations are located in the low-complexity C terminal domain and the pathogenicity of this variant, which is situated adjacent to the dominant DNA/RNA-binding domain RRM1, was unknown. Our 3D modelling showed that K181E and K263E, but not D169G, were predicted to reduce the positive charge within the nucleotide binding site. Here we have confirmed that K181E and K263E, but not D169G, disrupted RNA binding to these mutant proteins and abolished splicing of its endogenous RNA target *POLDIP3*. The loss of RNA binding by these two mutants was associated with a dramatic increase in TDP-43

protein phosphorylation, insolubility and aggregation, predominantly within the nucleus and to a lesser extent in the cytoplasm. We have demonstrated that wild-type TDP-43 is recruited to mutant aggregates that may exert a dominant-negative effect on RNA processing in the nucleus and cytoplasm.

TDP-43-mediated RNA regulation in health and disease

As a DNA/RNA-binding protein, TDP-43 is known to physically bind to mRNAs and miRNAs to regulate their splicing, stability, transport and translation (Ayala *et al.*, 2005; Buratti *et al.*, 2010; Polymenidou *et al.*, 2011; Tollervey *et al.*, 2011; Humphrey *et al.*, 2017). In addition to its role in normal RNA processing, TDP-43 has recently been shown to serve as a chaperone for toxic RNA, such as the UGAA repeat expansion associated with spinocerebellar ataxia type 31 (SCA31) (Niimi *et al.*, 2013; Ishiguro *et al.*, 2017). Functional disruption of TDP-43 RRM domains abolishes this interaction and results in the accumulation of (UGAA)_n RNA foci and repeat-associated pentapeptide, which leads to neurodegeneration (Ishiguro *et al.*, 2017). On the other hand, because of its role in RNA regulation, changes in TDP-43 protein levels impact on a vast number of its target RNAs, leading to alterations in the levels and splicing patterns of the cellular RNA profile (Polymenidou *et al.*, 2011; Zhang *et al.*, 2012). Knockdown of TDP-43 in cells or animals impacts widely on the levels and splicing pattern of a vast number of RNA transcripts (Polymenidou *et al.*, 2011; Ling *et al.*, 2015). Whereas the investigations into altered RNA profiles of ALS patients verify some of the changes observed in the knockdown study, the variance between human studies are simply too big to draw a consistent conclusion (Polymenidou *et al.*, 2011; Shiga *et al.*, 2012; Brohawn *et al.*, 2016; D'Erchia *et al.*, 2017).

A loss-of-function hypothesis has long been speculated as a mechanism underlying TDP-43-associated disease pathogenesis. Systematic knockout of TDP-43 in mice results in embryonic lethality (Kraemer *et al.*, 2010; Sephton *et al.*, 2010; Wu *et al.*, 2010) indicating that TDP-43 plays a crucial irreplaceable role during early embryo development. On the other hand, targeted depletion of TDP-43 in adult mouse motor neurons induces ALS-like progressive motor dysfunction and muscle atrophy (Wu *et al.*, 2012; Iguchi *et al.*, 2013), with similar results reported in *Drosophila* (Feiguin *et al.*, 2009; Fiesel *et al.*, 2010; Lin *et al.*, 2011; Diaper *et al.*, 2013) and *Caenorhabditis elegans* (Vaccaro *et al.*, 2012; Zhang *et al.*, 2012). Collectively, these studies indicate that TDP-43 plays an important role in maintaining the function and wellbeing of motor neurons. Interestingly, knockdown of endogenous TDP-43 shows the same impact on *POLDIP3* splicing as overexpression of wild-type TDP-43 alone (Figs 4C and 5D) (Fiesel *et al.*, 2010; Shiga *et al.*, 2012; Suzuki *et al.*, 2015), which indicates that TDP-43 needs to be maintained at a critical level, lower and




Figure 7 Disruption of cytoplasmic TDP-43 RNA binding aggravates TDP-43 proteinopathy. (A) HEK293T cells expressing GFP-TDP-43 constructs for 48 h followed by fractionation. GFP and phospho-TDP-43-specific antibodies were used to visualize total GFP-TDP-43 and phospho-TDP-43. Endogenous TDP-43 proteins are shown by TDP-43 antibody, and actin is shown as a loading control. (B–E) HEK293T cells expressing GFP-TDP-43 for 48 h were fixed and stained with phospho-TDP-43 (red), p62 (magenta; D) and ubiquitin (magenta; E). DAPI (blue) is used to visualize the nucleus. Scale bar = 10 μ m. The percentage of GFP-dNLS and GFP-dNLS K181E TDP-43 aggregation were quantified via cell counting as described before (Lee *et al.*, 2013). Means and SEMs are shown in C. All experiments were repeated at least three times.

higher protein levels are both likely to result in function disturbance and eventual cytotoxicity.

RRM1 has a very high affinity for RNA and plays a major role in mediating TDP-43/RNA interactions whereas RRM2 has a lower affinity for RNA and has a predominantly regulatory function (Buratti and Baralle, 2001; Lukavsky *et al.*, 2013; Kuo *et al.*, 2014). Functional mutation or complete deletion of the RRM2 domain has a limited impact on RNA binding (Buratti and Baralle, 2001); however, we have shown that both the K181E and K263E mutations completely abolish the binding of TDP-43 to its target RNA, and implying that the RRM2 does play an important role in RNA processing. The loss of RNA binding generated abundant insoluble hyperphosphorylated TDP-43 aggregates which are the hallmark of TDP-43 proteinopathy in FTD/ALS supports the case that these mutations are pathogenic. Interestingly, unlike the C-terminal mutations clustered in the glycine-rich domain that do not affect RNA binding, both K181E and K263E have been identified in families with FTD with or without ALS phenotypes. Whereas TDP-43 proteinopathy is commonly seen in tau-negative FTD, the mutations in TDP-43 found in FTD are still rare. Our study showed that in addition to not binding to RNA, both K181E and K26E mutations increase the insolubility and hyperphosphorylation of TDP-43. It is not yet clear whether this would subsequently trigger a distinct pathogenesis mechanism that is more likely to affect cognitive function. Further *in vivo* studies are needed to investigate the link between the loss of TDP-43 RNA binding and the cognitive dysfunction.

The presence of TDP-43 cytoplasmic inclusions is the hallmark of ALS and FTD but nuclear clearing is not always present, particularly in spinal cord motor neurons in ALS (Neumann *et al.*, 2007; van der Zee *et al.*, 2009; Weihl, 2011). Many cellular and animal models of TDP-43 overexpression show neurotoxicity in the absence of nuclear clearance (Barmada *et al.*, 2010; Mitchell *et al.*, 2015; Liu *et al.*, 2017) thus the aggregates themselves may be directly toxic to multiple cellular processes involving; intracellular transport, endoplasmic reticulum, mitochondria and proteostasis as a gain-of-function mechanism. They could also lead to the sequestration of soluble TDP-43 in the periphery, causing loss of normal TDP-43 protein transport and translation as a dominant-negative effect. TDP-43 RRM mutant proteins may be unable to process RNA and therefore auto-regulate its own translation, they do form aggregates and can sequester wild-type protein so both gain- and loss-of-function effects may contribute to neurodegeneration.

RNA chaperone

Interestingly, not only can the TDP-43 protein act as a chaperone to protect neurons from toxic RNA (Ishiguro *et al.*, 2017), RNA may in turn play a role in keeping TDP-43 soluble and preventing it from aggregating. Target single-stranded DNA or RNA has been shown to

enhance TDP-43 protein solubility *in vitro* (Huang *et al.*, 2013; Sun *et al.*, 2014) and the addition of an RNA-binding domain to the aggregation-prone *E. coli* lysol tRNA synthetase increased its protein folding and solubility in the presence of RNA (Choi *et al.*, 2008). On the other hand, TDP-43 containing the artificial mutations F147/149L, which functionally disrupt the RRM1, forms nuclear aggregates in cellular models and remains insoluble following the addition of RNA (Ayala *et al.*, 2008; Huang *et al.*, 2013). These results are consistent with our observation that RNA-free TDP-43 misfolds, becomes hyperphosphorylated and aggregates in the nucleus and cytoplasm indicates that the interaction with RNA plays an important role in maintaining TDP-43 protein solubility, and could be explored as a mean of therapeutic intervention for ALS.

In conclusion, we have identified a novel mutation adjacent to the RRM1 domain in a father and son with ALS and ALS/FTD. RRM domains show marked evolutionary conservation and variation largely absent from human genome databases. We have shown that two TDP-43 mutations, adjacent to either RRM domain, will abolish RNA binding and promote the formation of hyperphosphorylated, insoluble TDP-43 aggregates that are the hallmark of FTD and ALS, providing functional evidence that these mutations are likely to be pathogenic. Mutant TDP-43 aggregates may be directly toxic but they can also sequester wild-type TDP-43 protein and the loss of RNA processing function, including the autoregulation of *TARDBP* (TDP-43) mRNA, would be predicted to affect a multitude of important cellular pathways that could lead to neurodegeneration. As more wild-type TDP-43 becomes trapped within aggregates, less soluble TDP-43 is available to the cell. Eventually the RNA binding deficient mutant TDP-43 can deprive the cell of its functional RNA processing counterpart, resulting in a dominant-negative loss-of-function. Furthermore, our studies imply that RNA binding to TDP-43 can inhibit its aggregation, which may open new avenues for therapeutic intervention.

Acknowledgements

We thank London Neurodegenerative Diseases Brain Bank which is funded through the Medical Research Council and Brains for Dementia Research (jointly funded by Alzheimer's Research UK and the Alzheimer's Society), for the support in processing and analysing patient tissues. We also thank Dr. Stephen R. Martin from the Francis Crick Institute in London, UK, for technical support with biolayer interferometry experiments and the King's College NMR Centre.

Funding

Funding for this work was provided by a Strategic Grant Award from the Medical Research Council and Wellcome

Trust (089701/Z/09/Z). Additional funding was from the Motor Neurone Disease Association (Shaw/Nov14/985-797) and the UK Dementia Research Institute which is funded by the Medical Research Council, Alzheimer's Society and Alzheimer's Research UK. The work was also supported by the Francis Crick Institute through provision of access to the MRC Biomedical NMR Centre. The Francis Crick Institute receives its core funding from Cancer Research UK (FC001029), The UK Medical Research Council (FC001029) and the Wellcome Trust (FC001029). C.E.S. received salary support from the National Institute for Health Research (NIHR) Dementia Biomedical Research Unit at South London and Maudsley National Health Service (NHS) Foundation Trust and King's College London and B.N.S. is funded by the Medical Research Foundation (MRF)(MRF-060-0003-RG-SMITH).

Competing interests

The authors report no competing interests.

Supplementary material

Supplementary material is available at *Brain* online.

References

- Afroz T, Hock EM, Ernst P, Foglieni C, Jambeau M, Gilhespy LAB, et al. Functional and dynamic polymerization of the ALS-linked protein TDP-43 antagonizes its pathologic aggregation. *Nat Commun* 2017; 8: 45.
- Arai T, Nonaka T, Hasegawa M, Akiyama H, Yoshida M, Hashizume Y, et al. Neuronal and glial inclusions in frontotemporal dementia with or without motor neuron disease are immunopositive for p62. *Neurosci Lett* 2003; 342: 41–4.
- Ash PE, Zhang YJ, Roberts CM, Saldi T, Hutter H, Buratti E, et al. Neurotoxic effects of TDP-43 overexpression in *C. elegans*. *Hum Mol Genet* 2010; 19: 3206–18.
- Austin JA, Wright GS, Watanabe S, Grossmann JG, Antonyuk SV, Yamanaka K, et al. Disease causing mutants of TDP-43 nucleic acid binding domains are resistant to aggregation and have increased stability and half-life. *Proc Natl Acad Sci U S A* 2014; 111: 4309–14.
- Ayala YM, De Conti L, Avendano-Vazquez SE, Dhir A, Romano M, D'Ambrogio A, et al. TDP-43 regulates its mRNA levels through a negative feedback loop. *EMBO J* 2011; 30: 277–88.
- Ayala YM, Pantano S, D'Ambrogio A, Buratti E, Brindisi A, Marchetti C, et al. Human, *Drosophila*, and *C.elegans* TDP43: nucleic acid binding properties and splicing regulatory function. *J Mol Biol* 2005; 348: 575–88.
- Ayala YM, Zago P, D'Ambrogio A, Xu YF, Petrucelli L, Buratti E, et al. Structural determinants of the cellular localization and shuttling of TDP-43. *J Cell Sci* 2008; 121: 3778–85.
- Barmada SJ, Skibinski G, Korb E, Rao EJ, Wu JY, Finkbeiner S. Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis. *J Neurosci* 2010; 30: 639–49.
- Belly A, Moreau-Gachelin F, Sadoul R, Goldberg Y. Delocalization of the multifunctional RNA splicing factor TLS/FUS in hippocampal neurones: exclusion from the nucleus and accumulation in dendritic granules and spine heads. *Neurosci Lett* 2005; 379: 152–7.
- Bhardwaj A, Myers MP, Buratti E, Baralle FE. Characterizing TDP-43 interaction with its RNA targets. *Nucleic Acids Res* 2013; 41: 5062–74.
- Bilican B, Serio A, Barmada SJ, Nishimura AL, Sullivan GJ, Carrasco M, et al. Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability. *Proc Natl Acad Sci U S A* 2012; 109: 5803–8.
- Brettschneider J, Del Tredici K, Toledo JB, Robinson JL, Irwin DJ, Grossman M, et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. *Ann Neurol* 2013; 74: 20–38.
- Brohawn DG, O'Brien LC, Bennett JP, Jr. RNAseq analyses identify tumor necrosis factor-mediated inflammation as a major abnormality in ALS spinal cord. *PLoS One* 2016; 11: e0160520.
- Buratti E. Functional significance of TDP-43 mutations in disease. *Adv Genet* 2015; 91: 1–53.
- Buratti E, Baralle FE. Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of CFTR exon 9. *J Biol Chem* 2001; 276: 36337–43.
- Buratti E, Brindisi A, Giombi M, Tisminetzky S, Ayala YM, Baralle FE. TDP-43 binds heterogeneous nuclear ribonucleoprotein A/B through its C-terminal tail: an important region for the inhibition of cystic fibrosis transmembrane conductance regulator exon 9 splicing. *J Biol Chem* 2005; 280: 37572–84.
- Buratti E, De Conti L, Stuni C, Romano M, Baralle M, Baralle F. Nuclear factor TDP-43 can affect selected microRNA levels. *FEBS J* 2010; 277: 2268–81.
- Che MX, Jiang LL, Li HY, Jiang YJ, Hu HY. TDP-35 sequesters TDP-43 into cytoplasmic inclusions through binding with RNA. *FEBS Lett* 2015; 589: 1920–8.
- Chen HJ, Mitchell JC, Novoselov S, Miller J, Nishimura AL, Scotter EL, et al. The heat shock response plays an important role in TDP-43 clearance: evidence for dysfunction in amyotrophic lateral sclerosis. *Brain* 2016; 139: 1417–32.
- Choi SI, Han KS, Kim CW, Ryu KS, Kim BH, Kim KH, et al. Protein solubility and folding enhancement by interaction with RNA. *PLoS One* 2008; 3: e2677.
- Colombrita C, Zennaro E, Fallini C, Weber M, Sommacal A, Buratti E, et al. TDP-43 is recruited to stress granules in conditions of oxidative insult. *J Neurochem* 2009; 111: 1051–61.
- D'Ambrogio A, Buratti E, Stuni C, Guarnaccia C, Romano M, Ayala YM, et al. Functional mapping of the interaction between TDP-43 and hnRNP A2 in vivo. *Nucleic Acids Res* 2009; 37: 4116–26.
- D'Erchia AM, Gallo A, Manzari C, Raho S, Horner DS, Chiara M, et al. Massive transcriptome sequencing of human spinal cord tissues provides new insights into motor neuron degeneration in ALS. *Sci Rep* 2017; 7: 10046.
- Diaper DC, Adachi Y, Sutcliffe B, Humphrey DM, Elliott CJ, Stepto A, et al. Loss and gain of *Drosophila* TDP-43 impair synaptic efficacy and motor control leading to age-related neurodegeneration by loss-of-function phenotypes. *Hum Mol Genet* 2013; 22: 1539–57.
- Dion PA, Daoud H, Rouleau GA. Genetics of motor neuron disorders: new insights into pathogenic mechanisms. *Nat Rev Genet* 2009; 10: 769–82.
- Fallini C, Bassell GJ, Rossoll W. The ALS disease protein TDP-43 is actively transported in motor neuron axons and regulates axon outgrowth. *Hum Mol Genet* 2012; 21: 3703–18.
- Feiguin F, Godena VK, Romano G, D'Ambrogio A, Klima R, Baralle FE. Depletion of TDP-43 affects *Drosophila* motoneurons terminal synapses and locomotive behavior. *FEBS Lett* 2009; 583: 1586–92.
- Fiesel FC, Voigt A, Weber SS, Van den Haute C, Waldenmaier A, Gornier K, et al. Knockdown of transactive response DNA-binding protein (TDP-43) downregulates histone deacetylase 6. *EMBO J* 2010; 29: 209–21.
- Geser F, Brandmeir NJ, Kwong LK, Martinez-Lage M, Elman L, McCluskey L, et al. Evidence of multisystem disorder in whole-

- brain map of pathological TDP-43 in amyotrophic lateral sclerosis. *Arch Neurol* 2008; 65: 636–41.
- Goyal NA, Mozaffar T. Experimental trials in amyotrophic lateral sclerosis: a review of recently completed, ongoing and planned trials using existing and novel drugs. *Exp Opin Investig Drugs* 2014; 23: 1541–51.
- Hans F, Fiesel FC, Strong JC, Jackel S, Rasse TM, Geisler S, et al. UBE2E ubiquitin-conjugating enzymes and ubiquitin isopeptidase Y regulate TDP-43 protein ubiquitination. *J Biol Chem* 2014; 289: 19164–79.
- Huang YC, Lin KF, He RY, Tu PH, Koubek J, Hsu YC, et al. Inhibition of TDP-43 aggregation by nucleic acid binding. *PLoS One* 2013; 8: e64002.
- Humphrey J, Emmett W, Fratta P, Isaacs AM, Plagnol V. Quantitative analysis of cryptic splicing associated with TDP-43 depletion. *BMC Med Genomics* 2017; 10: 38.
- Igaz LM, Kwong LK, Lee EB, Chen-Plotkin A, Swanson E, Unger T, et al. Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice. *J Clin Invest* 2011; 121: 726–38.
- Iguchi Y, Katsuno M, Niwa J, Takagi S, Ishigaki S, Ikenaka K, et al. Loss of TDP-43 causes age-dependent progressive motor neuron degeneration. *Brain* 2013; 136: 1371–82.
- Ishiguro T, Sato N, Ueyama M, Fujikake N, Sellier C, Kanegami A, et al. Regulatory role of RNA chaperone TDP-43 for RNA misfolding and repeat-associated translation in SCA31. *Neuron* 2017; 94: 108–24 e7.
- Johnson BS, Snead D, Lee JJ, McCaffery JM, Shorter J, Gitler AD. TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. *J Biol Chem* 2009; 284: 20329–39.
- Johnston CA, Stanton BR, Turner MR, Gray R, Blunt AH, Butt D, et al. Amyotrophic lateral sclerosis in an urban setting: a population based study of inner city London. *J Neurol* 2006; 253: 1642–3.
- Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ, Vande Velde C, et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. *Nat Genet* 2008; 40: 572–4.
- Kovacs GG, Murrell JR, Horvath S, Haraszti L, Majtenyi K, Molnar MJ, et al. TARDBP variation associated with frontotemporal dementia, supranuclear gaze palsy, and chorea. *Mov Disord* 2009; 24: 1843–7.
- Kraemer BC, Schuck T, Wheeler JM, Robinson LC, Trojanowski JQ, Lee VM, et al. Loss of murine TDP-43 disrupts motor function and plays an essential role in embryogenesis. *Acta Neuropathol* 2010; 119: 409–19.
- Kuo PH, Chiang CH, Wang YT, Doudeva LG, Yuan HS. The crystal structure of TDP-43 RRM1-DNA complex reveals the specific recognition for UG- and TG-rich nucleic acids. *Nucleic Acids Res* 2014; 42: 4712–22.
- Kuo PH, Doudeva LG, Wang YT, Shen CK, Yuan HS. Structural insights into TDP-43 in nucleic-acid binding and domain interactions. *Nucleic Acids Res* 2009; 37: 1799–808.
- Lagier-Tourenne C, Polymenidou M, Cleveland DW. TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration. *Hum Mol Genet* 2010; 19: R46–64.
- Lee YB, Chen HJ, Peres JN, Gomez-Deza J, Attig J, Stalekar M, et al. Hexanucleotide repeats in ALS/FTD form length-dependent RNA foci, sequester RNA binding proteins, and are neurotoxic. *Cell Rep* 2013; 5: 1178–86.
- Lin MJ, Cheng CW, Shen CK. Neuronal function and dysfunction of *Drosophila* dTDP. *PLoS One* 2011; 6: e20371.
- Ling SC, Albuquerque CP, Han JS, Lagier-Tourenne C, Tokunaga S, Zhou H, et al. ALS-associated mutations in TDP-43 increase its stability and promote TDP-43 complexes with FUS/TLS. *Proc Natl Acad Sci U S A* 2010; 107: 13318–23.
- Ling JP, Pletnikova O, Troncoso JC, Wong PC. TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD. *Science* 2015; 349: 650–5.
- Liu G, Coyne AN, Pei F, Vaughan S, Chaung M, Zarnescu DC, et al. Endocytosis regulates TDP-43 toxicity and turnover. *Nat Commun* 2017; 8: 2092.
- Liu-Yesucevitz L, Bassell GJ, Gitler AD, Hart AC, Klann E, Richter JD, et al. Local RNA translation at the synapse and in disease. *J Neurosci* 2011; 31: 16086–93.
- Ludolph A, Drory V, Hardiman O, Nakano I, Ravits J, Robberecht W, et al. A revision of the El Escorial criteria-2015. *Amyotroph Lateral Scler Frontotemporal Degener* 2015; 16: 291–2.
- Lukavsky PJ, Daujotyte D, Tollervey JR, Ule J, Stuani C, Buratti E, et al. Molecular basis of UG-rich RNA recognition by the human splicing factor TDP-43. *Nat Struct Mol Biol* 2013; 20: 1443–9.
- Mackenzie IR, Bigio EH, Ince PG, Geser F, Neumann M, Cairns NJ, et al. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. *Ann Neurol* 2007; 61: 427–34.
- Mackenzie IR, Rademakers R, Neumann M. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. *Lancet Neurol* 2010; 9: 995–1007.
- March ZM, King OD, Shorter J. Prion-like domains as epigenetic regulators, scaffolds for subcellular organization, and drivers of neurodegenerative disease. *Brain Res* 2016; 1647: 9–18.
- Marley J, Lu M, Bracken C. A method for efficient isotopic labeling of recombinant proteins. *J Biomol NMR* 2001; 20: 71–5.
- McDonald KK, Aulas A, Destroismaisons L, Pickles S, Beleac E, Camu W, et al. TAR DNA-binding protein 43 (TDP-43) regulates stress granule dynamics via differential regulation of G3BP and TIA-1. *Hum Mol Genet* 2011; 20: 1400–10.
- Mitchell JC, Constable R, So E, Vance C, Scotter E, Glover L, et al. Wild type human TDP-43 potentiates ALS-linked mutant TDP-43 driven progressive motor and cortical neuron degeneration with pathological features of ALS. *Acta Neuropathol Commun* 2015; 3: 36.
- Neumann M, Mackenzie IR, Cairns NJ, Boyer PJ, Markesbery WR, Smith CD, et al. TDP-43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations. *J Neuropathol Exp Neurol* 2007; 66: 152–7.
- Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. *Science* 2006; 314: 130–3.
- Niimi Y, Takahashi M, Sugawara E, Umeda S, Obayashi M, Sato N, et al. Abnormal RNA structures (RNA foci) containing a pentanucleotide repeat (UGGAA)_n in the Purkinje cell nucleus is associated with spinocerebellar ataxia type 31 pathogenesis. *Neuropathology* 2013; 33: 600–11.
- Nishimura AL, Zupunski V, Troakes C, Kathe C, Fratta P, Howell M, et al. Nuclear import impairment causes cytoplasmic trans-activation response DNA-binding protein accumulation and is associated with frontotemporal lobar degeneration. *Brain* 2010; 133: 1763–71.
- Nonaka T, Arai T, Buratti E, Baralle FE, Akiyama H, Hasegawa M. Phosphorylated and ubiquitinated TDP-43 pathological inclusions in ALS and FTLU are recapitulated in SH-SY5Y cells. *FEBS Lett* 2009; 583: 394–400.
- Pamphlett R, Luquin N, McLean C, Jew SK, Adams L. TDP-43 neuropathology is similar in sporadic amyotrophic lateral sclerosis with or without TDP-43 mutations. *Neuropathol Appl Neurobiol* 2009; 35: 222–5.
- Polymenidou M, Lagier-Tourenne C, Hutt KR, Huelga SC, Moran J, Liang TY, et al. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. *Nat Neurosci* 2011; 14: 459–68.
- Rutherford NJ, Zhang YJ, Baker M, Gass JM, Finch NA, Xu YF, et al. Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis. *PLoS Genet* 2008; 4: e1000193.

- Scotter EL, Chen HJ, Shaw CE. TDP-43 Proteinopathy and ALS: insights into disease mechanisms and therapeutic targets. *Neurotherapeutics* 2015; 12: 352–63.
- Sephton CF, Good SK, Atkin S, Dewey CM, Mayer P, 3rd, Herz J, et al. TDP-43 is a developmentally regulated protein essential for early embryonic development. *J Biol Chem* 2010; 285: 6826–34.
- Shiga A, Ishihara T, Miyashita A, Kuwabara M, Kato T, Watanabe N, et al. Alteration of POLDIP3 splicing associated with loss of function of TDP-43 in tissues affected with ALS. *PLoS One* 2012; 7: e43120.
- Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. *Science* 2008; 319: 1668–72.
- Stallings NR, Puttaparthi K, Luther CM, Burns DK, Elliott JL. Progressive motor weakness in transgenic mice expressing human TDP-43. *Neurobiol Dis* 2010; 40: 404–14.
- Sun Y, Arslan PE, Won A, Yip CM, Chakrabartty A. Binding of TDP-43 to the 3'UTR of its cognate mRNA enhances its solubility. *Biochemistry* 2014; 53: 5885–94.
- Suzuki H, Shibagaki Y, Hattori S, Matsuoka M. Nuclear TDP-43 causes neuronal toxicity by escaping from the inhibitory regulation by hnRNPs. *Hum Mol Genet* 2015; 24: 1513–27.
- Synofzik M, Born C, Rominger A, Lummel N, Schols L, Biskup S, et al. Targeted high-throughput sequencing identifies a TARDBP mutation as a cause of early-onset FTD without motor neuron disease. *Neurobiol Aging* 2014; 35: 1212e1–5.
- Tan CF, Eguchi H, Tagawa A, Onodera O, Iwasaki T, Tsujino A, et al. TDP-43 immunoreactivity in neuronal inclusions in familial amyotrophic lateral sclerosis with or without SOD1 gene mutation. *Acta Neuropathol* 2007; 113: 535–42.
- Tollervey JR, Curk T, Rogelj B, Briesse M, Cereda M, Kayikci M, et al. Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. *Nat Neurosci* 2011; 14: 452–8.
- Vaccaro A, Tauffenberger A, Ash PE, Carlomagno Y, Petrucelli L, Parker JA. TDP-1/TDP-43 regulates stress signaling and age-dependent proteotoxicity in *Caenorhabditis elegans*. *PLoS Genet* 2012; 8: e1002806.
- van der Zee J, Pirici D, Van Langenhove T, Engelborghs S, Vandenberghe R, Hoffmann M, et al. Clinical heterogeneity in 3 unrelated families linked to VCP p.Arg159His. *Neurology* 2009; 73: 626–32.
- Vanden Broeck L, Kleinberger G, Chapuis J, Gistelincx M, Amouyel P, Van Broeckhoven C, et al. Functional complementation in *Drosophila* to predict the pathogenicity of TARDBP variants: evidence for a loss-of-function mechanism. *Neurobiol Aging* 2015; 36: 1121–9.
- Weihl CC. Valosin containing protein associated fronto-temporal lobar degeneration: clinical presentation, pathologic features and pathogenesis. *Curr Alzheimer Res* 2011; 8: 252–60.
- Wijesekera LC, Leigh PN. Amyotrophic lateral sclerosis. *Orphanet J Rare Dis* 2009; 4: 3.
- Wils H, Kleinberger G, Janssens J, Pereson S, Joris G, Cuij I, et al. TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration. *Proc Natl Acad Sci U S A* 2010; 107: 3858–63.
- Winton MJ, Igaz LM, Wong MM, Kwong LK, Trojanowski JQ, Lee VM. Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43) induces disease-like redistribution, sequestration, and aggregate formation. *J Biol Chem* 2008; 283: 13302–9.
- Wu LS, Cheng WC, Hou SC, Yan YT, Jiang ST, Shen CK. TDP-43, a neuro-pathosignature factor, is essential for early mouse embryogenesis. *Genesis* 2010; 48: 56–62.
- Wu LS, Cheng WC, Shen CK. Targeted depletion of TDP-43 expression in the spinal cord motor neurons leads to the development of amyotrophic lateral sclerosis-like phenotypes in mice. *J Biol Chem* 2012; 287: 27335–44.
- Yasuda K, Mili S. Dysregulated axonal RNA translation in amyotrophic lateral sclerosis. *Wiley Interdiscip Rev RNA* 2016; 7: 589–603.
- Zacco E, Grana-Montes R, Martin SR, de Groot NS, Alfano C, Tartaglia GG, et al. RNA as a key factor in driving or preventing self-assembly of the TAR DNA-binding protein 43. *J Mol Biol* 2019; 431: 1671–88.
- Zhang T, Hwang HY, Hao H, Talbot C Jr, Wang J. *Caenorhabditis elegans* RNA-processing protein TDP-1 regulates protein homeostasis and life span. *J Biol Chem* 2012; 287: 8371–82.